NorthSea Therapeutics Secures Orphan Drug Designations for Orziloben in Rare Liver Disease
Key Insights
NorthSea Therapeutics (search) received Orphan Drug Designations from both the FDA and EMA for orziloben, targeting intestinal failure associated liver disease (search) (IFALD (search)), a rare condition with no approved pharmacologic treatments.
Orziloben is a novel synthetic medium chain fatty acid analog designed to target multiple pathways including bile acid metabolism, liver inflammation, and fibrosis through specific receptor mechanisms.
The company is conducting a Phase 2 randomized, placebo-controlled trial evaluating two dosing regimens in adult IFALD (search) patients, with topline results expected in Q3 2026.
NorthSea Therapeutics (search) has achieved significant regulatory milestones for its lead candidate orziloben, receiving Orphan Drug Designations from both the U.S. Food and Drug Administration and the European Medicines Agency's Committee for Orphan Medicinal Products for the treatment of intestinal failure associated liver disease (search) (IFALD (search)). The drug had previously received rare pediatric disease designation from the FDA.
"We are pleased that orziloben has received ODD from both agencies. This recognition continues to reinforce the widespread need to treat rare liver diseases and the potential of orziloben," said Sophie Jeannin, Chief Medical Officer of NorthSea Therapeutics (search). "Orziloben is in a Phase 2 study for the treatment of IFALD (search), a rare, chronic life-threatening condition with no approved pharmacologic treatment options."
Novel Mechanism Targets Multiple Disease Pathways
Orziloben represents a first-in-class approach to treating IFALD (search) through its unique mechanism of action. The investigational drug is a fully synthetic medium chain fatty acid analog that is administered once daily and demonstrates high bioavailability. Unlike long chain fatty acids, orziloben is passively absorbed from the gut and directly targets the liver via the portal vein.
The drug is specifically engineered to resist rapid metabolism in the liver, overcoming a primary limitation of unmodified medium chain fatty acids as therapeutic agents. Orziloben targets multiple fatty acid sensitive receptors that address key aspects of IFALD (search) pathophysiology: PPAR-α (search) for dysregulated bile acid metabolism, GPR84 (search) for liver inflammation, and PPAR-γ (search) for fibrosis.
Addressing Critical Unmet Medical Need
IFALD (search) represents one of the most serious and life-threatening conditions in patients with intestinal failure receiving parenteral nutrition. The disease is characterized by progressive hepatic dysfunction, manifesting as persistent cholestasis, hepatic inflammation, fibrosis, steatosis, and ultimately biliary cirrhosis (search).
The patient population facing this condition is substantial within the rare disease space. There are an estimated 40,000 adult patients and 3,600 pediatric patients in the United States with chronic intestinal failure (search). Of these, approximately 15-40% of adults and approximately 40-60% of children develop IFALD (search).
"IFALD (search) is a devastating liver disease for patients with chronic intestinal failure (search) and can progress to end stage liver disease," said Rob de Ree, Chief Executive Officer of NorthSea Therapeutics (search). "If approved, orziloben has the potential to be the standard of care in the U.S. for the treatment of IFALD."
Phase 2 Trial Design and Timeline
The company is currently conducting a randomized, double-blind, Phase 2, placebo-controlled study evaluating orziloben in adult patients with IFALD (search). The trial employs a unique dosing strategy, evaluating both orziloben 800mg once daily versus placebo for 4 weeks of treatment, and orziloben 1200mg once daily for 12 weeks.
The study is designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects. Primary endpoints include evaluating reductions from baseline in key liver function markers: alkaline phosphatase, gamma-glutamyl transferase (GGT), aspartate transaminase (AST), alanine transaminase (ALT), and bilirubin. Topline results are expected in the third quarter of 2026.
Early clinical data from a Phase 1 study in healthy volunteers demonstrated a favorable tolerability profile for orziloben, with most treatment-emergent adverse effects being mild.
Platform Technology for Rare Liver Diseases
NorthSea Therapeutics (search) leverages its proprietary structurally engineered fatty acids (SEFAs) platform to develop novel treatments for rare liver diseases. The platform is designed to target cholestatic, inflammatory, and fibrotic pathways, addressing the complex, multi-modal mechanisms underlying heterogeneous rare liver diseases.
The company, headquartered in the Netherlands with presence in the U.S. and Norway, is backed by prominent investors including Forbion, Ysios Capital, venBio, Novo Seeds, Sofinnova, BGV, and New Science Ventures.